RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2001; 86(03): 722-726
DOI: 10.1055/s-0037-1616130
DOI: 10.1055/s-0037-1616130
Review Articles
Thrombophilic Risk Factors in Patients with Central Retinal Vein Occlusion
Weitere Informationen
Publikationsverlauf
Received
18. September 2000
Accepted after resubmission
03. April 2001
Publikationsdatum:
14. Dezember 2017 (online)
Summary
Few and contrasting data are available on the prevalence of hemostatic risk factors in patients with central retinal vein occlusion (CRVO). Aim of this study was to investigate the metabolic and inherited risk factors for venous thrombosis in 100 CRVO patients (age: 59 yrs; range 18-77) and in 100 controls (age: 56 yrs; range 18-84). In patients homocysteine (Hcy) levels were significantly higher than in controls and were affected by the C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism (p <0.001). The prevalences of activated protein C resistance (APCR), factor V Leiden positivity, elevated PAI-1 and Lp(a) levels were significantly higher in patients with respect to controls. At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p <0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p <0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p <0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p <0.05), were independent risk factors for CRVO. These data demonstrate a potential role of hemostatic risk factors in the pathophysiology of CRVO.
-
References
- 1 Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-47.
- 2 Fong AC, Schatz H, Mc Donald HR, Burton TC, Maberley AL, Joffe L, Zegarra H, Nadel AJ, Johnson RN. Central retinal vein occlusion in young adults (papillophlebitis). Retina 1992; 12: 3-11.
- 3 Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein thrombosis: a case-control study. Ophthalmology 1992; 99: 509-14.
- 4 Dodson PM, Clough CG, Downes SM, Kritzinger EE. Does type II diabetes predispose to retinal vein occlusion?. Eur J Ophthalmol 1993; 3: 109-13.
- 5 The Central Vein Occlusion Study Group.. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-91.
- 6 Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97: 1543-8.
- 7 Laatikanen L, Kohner EM, Khoury D. Panretinal photocoagulation in central retinal vein occlusion: a randomized controlled clinical study. Br J Ophthalmol 1977; 61: 741-53.
- 8 Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80-6.
- 9 Bernard AG, Chanabel A, Lelong F. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 1994; 101: 1483-7.
- 10 Bandello F, Vigano D’Angelo S, Parlavecchia M, Tavola A, Della Valle P, Brancato R, D’Angelo A. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39-43.
- 11 Bertram B, Remky A, Arend O, Wolf S, Reim M. Protein C protein S and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4: 332-5.
- 12 Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation and activated protein C resistance in central retinal vein occusion: a population controlled study. Br J Ophthalmol 1996; 80: 203-8.
- 13 Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-2.
- 14 Scat Y, Morin Y, Morel C, Haut J. Retinal vein occlusion and resistance to activated protein C. J Fr Ohpthalmol 1995; 18: 758-62.
- 15 Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated protein C resistance, factor V Leiden and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116: 577-9.
- 16 Graham SL, Goldberg I, Murray B, Beaumont P, Chong BH. Activated protein C resistance: low incidence in glaucomatous disc hemorrhage and central retinal vein occlusion. Aust N Z Ophthalmol 1996; 24: 199-205.
- 17 Salomon O, Moisseiev J, Rosenberg N, Vidne O, Yassur I, Zivelin A, Treister G, Steinberg DM, Seligsohn U. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coag Fibrinol 1998; 9: 617-22.
- 18 Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-6.
- 19 Hansen L, Kristensen HL, Bek T, Ingerslev J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand 2000; 78: 523-6.
- 20 Albisinni R, Coppola A, Loffredo M, Cerbone AM, Di Minno G, Greco GM. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-3.
- 21 Glueck CJ, Bell H, Vadlamani L, Gupta A, Fontaine RN, Wang P, Stroop D, Gruppo R. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-9.
- 22 Delahousse B, Arsene S, Piquemal R, Iochmann S, Le Lez ML, Pouplard C, Gruel Y. The 20210A allele of the prothrombin gene is not a risk factor for retinal vein occlusion. Blood Coag Fibrinol 1998; 9: 447-8.
- 23 Larsson J, Hillarp A. The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion. Thromb Res 1999; 96: 323-7.
- 24 Coniglio M, Platania A, Di Nucci GD, Arcieri P, Modzrewska R, Mariani G. Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. Thromb Res 1996; 83: 183-8.
- 25 Glacet-Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G. Antiphospholipid antiodies in retinal vascular occlusions: a prospective study of 75 patients. Arch Ophthalmol 1994; 112: 790-5.
- 26 Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
- 27 Jacques PF, Bostom AG. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
- 28 Wenzler EM, Rademakers AJJM, Boers GHJ, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-7.
- 29 Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000; 78: 340-3.
- 30 Cahill M, Karabatzaki M, Meleady R, Refsum H, Ueland P, Shields D, Mooney D, Graham I. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 84: 154-7.
- 31 Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107: 1588-92.
- 32 Cahill M, Karabatzaki M, Donoghue C, Meleady R, Mynett-Johnson LA, Mooney D, Graham IM, Whitehead AS, Shields DS. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 2001; 85: 88-90.
- 33 Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 640-4.
- 34 Marcucci R, Prisco D, Brunelli T, Pepe G, Gori AM, Fedi S, Capanni M, Simonetti I, Federici G, Pastore A, Abbate R, Gensini GF. Tissue factor and homocysteine levels in ischemic heart disease are associated with angio-graphically documented clinical recurrences after coronary angioplasty. Thromb Haemost 2000; 83: 826-32.
- 35 Stein JH, Rosenson RS. Lipoprotein (a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170-6.
- 36 Williamson TH. Central retinal vein occlusion: what‘s the story?. Br J Ophthalmol 1997; 81: 698-704.
- 37 The Eye Disease Case Control Study Group.. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-54.
- 38 Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D, Fatini C, Capanni M, Simonetti I, Gensini GF. The high prevalence of high 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease. Thromb Haemost 1998; 79: 727-30.
- 39 Egerton W, Silberger J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocysteine after acute myocardial infarction. Am J Cardiol 1996; 77: 759-61.
- 40 Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
- 41 Tavola A, D’Angelo SV, Bandello F, Brancato R, Parlavecchia M, Safa O, D’Angelo A. Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein (a) levels: a case-report. Thromb Res 1995; 80: 327-31.